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Abstract
Background: Circulating tumor cells (CTCs) are typically collected into CellSave fixative tubes, which kills the cells,
but preserves their morphology. Currently, the clinical utility of CTCs is mostly limited to their enumeration. More
detailed investigation of CTC biology can be performed on live cells, but obtaining live CTCs is technically challenging,
requiring blood collection into biocompatible solutions and rapid isolation which limits transportation options. To
overcome the instability of CTCs, we formulated a sugar based cell transportation solution (SBTS) that stabilizes
cell viability at ambient temperature. In this study we examined the long term viability of human cancer cell lines,
primary cells and CTCs in human blood samples in the SBTS for transportation purposes.
Methods: Four cell lines, 5 primary human cells and purified human PBMCs were tested to determine the viability of
cells stored in the transportation solution at ambient temperature for up to 7 days. We then demonstrated viability of
MCF-7 cells spiked into normal blood with SBTS and stored for up to 7 days. A pilot study was then run on blood
samples from 3 patients with metastatic malignancies stored with or without SBTS for 6 days. CTCs were then
purified by Ficoll separation/microfilter isolation and identified using CTC markers. Cell viability was assessed
using trypan blue or CellTracker™ live cell stain.
Results: Our results suggest that primary/immortalized cell lines stored in SBTS remain ~90 % viable for > 72 h.
Further, MCF-7 cells spiked into whole blood remain viable when stored with SBTS for up to 7 days. Finally, live
CTCs were isolated from cancer patient blood samples kept in SBTS at ambient temperature for 6 days. No CTCs
were isolated from blood samples stored without SBTS.
Conclusions: In this proof of principle pilot study we show that viability of cell lines is preserved for days using
SBTS. Further, this solution can be used to store patient derived blood samples for eventual isolation of viable
CTCs after days of storage. Therefore, we suggest an effective and economical transportation of cancer patient
blood samples containing live CTCs can be achieved.
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Background
The primary mechanism of metastatic spread begins
with dissemination, or shedding, of cancerous epithelial
cells from tumor sites into the circulation. These circu-
lating tumor cells (CTCs) travel throughout the body,
adhere to organ vascular beds, infiltrate the tissue, grow
and impair organ function [1–3].
Animal studies have shown that organ colonization of
injected tumor cells is very efficient, i.e. ~80 % of injected
tumor cells extravasate into organs [4–7]. However, the
majority of those extravasated cells do not form tumors,
thus their metastatic potential through CTC dissemin-
ation is, in most cases, very inefficient. Despite ~106
tumor cells are being shed into the circulation per gram of
tumor tissue every 24 h, less than 1 % of shed CTCs re-
main alive 24 h after dissemination [8–11]. This loss of
CTC viability has been attributed to many factors includ-
ing fragility, shear stresses in the circulation, anoikis and
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destruction by the immune system [12–16]. Interestingly,
studies imply that the injected cancer cells that form pri-
mary tumors have different biological properties than their
progeny populating the metastatic tumors [17, 18].
Analyzing human CTCs is technically challenging be-
cause of their extreme rarity in cancer patient blood sam-
ples (commonly ≤ 10 CTCs among 109 total blood cells),
their inherent heterogeneity and instability [16, 19–21].
CellSearch® is the only FDA approved and clinically val-
idated CTC assay that isolates CTCs, used as a prog-
nostic indicator of survival for breast, prostate, and
colorectal cancer patients. This system was developed
based on affinity-based isolation procedures and bio-
marker presence [22–25]. The CellSearch® CTC Test
requires blood samples to be collected in CellSave tubes
which contain a fixative solution that allows storage of
blood samples for up to 3 days, but also kills the CTCs.
The need for CTC fixation is necessitated because of their
inherent fragility [19–21, 26, 27], but besides killing the
CTCs, fixation also crosslinks extra- and intracellular
biomolecules that can compromise some molecular
analysis [28, 29].
Examining live CTCs has the potential of advancing
the knowledge of cancer metastasis by interrogating the
underlying biological activity of cells which cannot be
accomplished on dead cells, i.e. mRNA profiling, cul-
turing, etc. [28–34]. While many devices and tech-
niques have been developed to capture live CTCs from
patient blood samples, the blood sample is usually
processed on-site and within hours of collection to re-
tain viability [30, 35–41]. Therefore, transportation of
live CTCs in blood samples between research institu-
tions is often not possible due to the high rate of CTC
senescence in whole blood.
We first examined the ability of the SBTS to preserve
viability in primary cells, cell lines and cancer cells
spiked into blood cells at ambient temperature for stor-
age/transportation purposes. We then extended our
studies, examining the effect of the SBTS on patient
blood samples with live CTCs. Our data suggest that
cells can be stored for days without harming the viabil-
ity of the cells and that CTCs in patient blood samples
can also be stored for 6 days at room temperature and
retain viability. While further studies on the potential
use of the SBTS to preserve live CTCs in transporting
blood samples is needed, we suggest that cells can be




The sugar based cell transportation solution (SBTS) is a
non-toxic proprietary mixture of high and low molecular
weight carbohydrates (HemSol™). CellSieve™ CTC micro-
filtration system from Creatv Microtech (Rockville, MD)
using a low-pressure vacuum system which isolates
CTCs based on size exclusion, > 7 micron, as previously
described [42–44]. Stains used on the CTCs were Cell-
Tracker™ Blue CMAC live cell stain (Thermo-Fisher).
FITC labeled Pan-cytokeratin clone C11 (Sigma), which
recognizes human cytokeratins 4, 5, 6, 8, 10, 13 and 18.
Phycoerythrin (PE) labeled anti-human epithelial cell
adhesion molecule (EpCAM), clone 1B7 (eBioscience).
Alexa Fluor® 594 labeled anti-human CD45, clone 2D1
(Novus) and DRAQ5™ fluorescent DNA probe (Thermo-
Fisher). Exposure times (and ex/em wavelengths of the
Leica microscope filters), respectively, were: Blue CMAC:
35 msec, (350 nm/460 nm); FITC-CK, 500 msec (470 nm/
525 nm); PE-EpCAM, 500 msec (546 nm/585 nm); Alexa
Fluor594 500 msec (594 nm/645 nm); . DRAQ5 600 msec
(640 nm/690 nm). Samples were analyzed using a Leica
fluorescent microscope and imaged with a Leica camera
and Leica Microsystems imaging software.
Cell lines, primary cells and blood samples
Chinese hamster ovary cells (CHO), human embryonic
kidney cells (HEK 293), human umbilical vein endothe-
lial cells (HUVEC) and human epithelial colorectal
adenocarcinoma cells (CACO-2) human breast cancer
epithelial cells (MCF-7), in addition to primary human
cells were purchased from ATCC. Peripheral blood
mononuclear cells (PBMCs) were isolated from whole
blood samples obtained from healthy volunteers using
Ficoll separation (GE Healthcare) as described by the
manufacturer. Healthy volunteer blood samples were
procured with signed informed consent and IRB ap-
proval by Western IRB. Patient blood samples were col-
lected with signed informed consent and an IRB with
Inova Fairfax Hospital.
Incubation of cells and cell lines with HemSol™
transportation solution
HemSol™ preservation experiments with primary human
hepatocytes, B-Cells, kidney cells, mesenchymal stem cells
and non-small cell (NSC) lung carcinoma were performed
in collaborations with AscentGene Inc. (Gaithersburg,
MD). Approximately 105–107 cells were kept in their re-
spective growth media prior to treatment with HemSol™.
Live cells were enumerated by trypan blue exclusion.
Cells were then mixed with concentrated HemSol™ (2-
6X) for a final concentration of 1X HemSol™. The cells
were then stored in the solution for the indicated time
at ambient temperature, after which the HemSol™ was
washed away using the respective cell media and live
cells determined using trypan blue exclusion and
noted in Table 1.
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Analysis of MCF-7 cells spiked into normal whole blood
with HemSol™ transportation solution
Human breast cancer cell line (MCF-7) was labeled with
CellTracker™ Green (Invitrogen) according to manufac-
turer’s protocols and cells were then washed to remove
remaining free dye. CellTracker™ Green is an intracellu-
lar stain that only labels live cells and is retained by cell
progeny, allowing for multigenerational tracking. Ap-
proximately 10,000 of the labeled MCF-7 cells were
added to 8 ml of normal whole blood. 4 ml of that blood
sample was then mixed with HemSol™ and 4 ml was in-
cubated without the HemSol™ at RT for 4 days. After the
incubation, the blood was filtered and the filters put into
tissue culture with DMEM, 10 % serum at 37 °C, 5 %
CO2 and imaged after 3 days in culture. A second set of
labeled MCF-7 cells were kept in whole blood for 7 days
at RT followed by filtration using the CellSieve™ CTC
micro-filtration system from Creatv Microtech, as previ-
ously described [42–44] and imaged.
Analysis of cancer patient blood samples incubated with
HemSol™ transportation solution
To determine the preservation of live CTCs in HemSol™,
duplicate whole blood samples (7.5 ml) from 1 breast
cancer patient, 1 pancreatic cancer patient and 1 lung
cancer patient were collected into EDTA vacutainers and
the contents of one tube immediately transferred to a
15 ml conical tube containing 6X concentrated Hem-
Sol™, which was diluted to 1X HemSol™ with the blood
and mixed for complete dispersal. The duplicate blood
sample was transferred to a conical tube containing PBS
at the same volume as the concentrated HemSol™, and
mixed similarly. The blood samples were kept for 6 days
at RT without agitation and then fractionated by mixing
the samples 1:1 with PBS and overlaying the samples
onto Ficoll. The samples were centrifuged at 400 × g for
30 min at 18 °C in 50-mL centrifuge tubes according to
manufacturer’s instructions. HemSol™ did not interfere
with the density separation of red blood cells from the
PBMC buffy coat layer. The collected buffy coat layer
was pelleted by centrifugation and resuspended in 1 ml
PBS with CellTracker™ Blue CMAC Dye cell live stain
(Invitrogen) for 45 min at RT according to manufac-
turer’s instructions. After incubation, unbound dye was
removed by centrifugation and resuspension of the cell
pellet in 2 ml PBS followed by re-centrifugation. The
resulting cell pellet was then resuspended in PBS con-
taining 1 % paraformaldehyde (PFA), 5 mM EDTA and
incubated for 20 min at RT. After fixation, the cells were
filtered using CellSieve™ micro-filtration system (Creatv
Microtech) [42–45] set at a flow rate of 5 ml/min. The
captured cells were then permeabilized with PBS con-
taining 0.4 % Triton X-100 in PBS, washed twice with
4 ml PBS and stained as previouly described [42–45].
Results and discussion
Analyzing physical parameters of cancer patient blood
samples are routine procedures performed in clinical
labs around the world. A recent addition to the arsenal
of clinical blood testing procedures in oncology practices
is the enumeration of circulating tumor cells (CTCs).
These are cancerous cells of epithelial origin that are
shed from solid tumors and found in the circulation of
many cancer patients which can be used as indicators
of patient survival. However, CTCs are fragile cells that
die and disintegrate rapidly in whole blood samples
[16, 19–21]. Therefore, enumeration of CTCs requires
patient blood collection into specialized tubes contain-
ing fixatives that preserve CTC morphology, but sacri-
fice viability. The blood samples collected into fixatives
Table 1 Viability of cells kept in SBTS for the indicated timea at ambient temperature. Cells (105-107), were mixed with SBTS and cell
viability was assessed using trypan-blue exclusion after washing and resuspending cells in their respective serum containing mediab
Cell Type Cell Condition Time in SBTS (Days)a % Live Cellsb
CHO Suspension 4 95–98
CHO Adherent 3 95–99
HEK 293 Adherent 3 92–98
HUVEC Suspension 3 90–98
HUVEC Adherent 3 93–96
CACO-2 Adherent 3 92–98
Primary hepatocytes Adherent 7 85–92
PBMC Suspension 3 > 95
B-Cells Suspension 4 95–98
Primary kidney cells Suspension 7 85–90
Mesenchymal stem cells Suspension 9 92–98
NSC lung carcinoma Suspension 3 80–92
Live cells were determined from at least 3 experiments
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keep cell integrity for at least 3 days, allowing them to
be transported to other labs for enumeration and further
analysis. However, many biological analyses are compro-
mised as cells are dead and imbued with fixative [28, 29].
Keeping CTCs alive in whole blood samples long enough
for timely and economical transportation is a challenge as
whole blood is an exceptionally harsh media for non-
hematopoietic cells.
The SBTS is a proprietary mixture of simple and
complex carbohydrates that was initially formulated to
stabilize human red blood cell (RBC) structure and
antigen properties upon desiccation for use in reference
labs [46]. Oxygen binding properties of desiccated
RBCs and platelet structure and function stored at 4 °C
for up to 2 weeks are also protected in the presence of
these carbohydrates [47, 48]. Those results prompted
us to examine whether the SBTS could also stabilize the
structure of live nucleated cells. Table 1 shows stabilization
of live cell kept in SBTS for 3–9 days at RT.
These data show that immortalized, and primary cells
both adherent and in suspension are kept live in SBTS
for at least 3 days at ambient temperature. Of special no-
tice is that anchorage dependent cells, including human
umbilical vein endothelial cells (HUVEC), human pri-
mary kidney cells, Chinese hamster ovary cells (CHO)
and human non-small cell (NSC) lung carcinoma cells
remain viable in suspension for at least 3 days in SBTS.
The positive results of these studies prompted us to
examine whether SBTS can preserve cells in other in-
hospitable media, such as whole blood. Many CTCs are
of epithelial origin, which means that they are generally
anchorage dependent and undergo apoptosis when in
suspension.
Before analyzing CTCs from patient blood samples, we
first performed experiments with live MCF-7 epithelial
breast cancer cells, which are also anchorage dependent,
spiked into whole blood as described [42]. CellTracker™
Green pre-labeled MCF-7 cells were spiked into 4 ml of
normal whole blood with or without SBTS. This Cell-
Tracker™ dye in a non-fluorescent cell permeable ester-
ase substrate that becomes fluorescent after cleavage by
intracellular esterases. The cleavage traps the fluorescent
dye inside the cells and it is retained even after cell divi-
sions, however the dye is lost when the integrity of the
cell is compromised.
After 4 days in whole blood at RT, the MCF-7 cells
were isolated using CellSieve™ microfilters and the filters
were put into cell culture media and allowed to grow for
3 days. Figure 1a shows that MCF-7 cells spiked into
whole peripheral blood treated with SBTS were able to
proliferate and formed colonies post-isolation. In con-
trast, MCF-7 cells isolated from whole blood in the ab-
sence of SBTS had far fewer viable cells and none of the
cells proliferated, even after 7 days in culture (Fig. 1b).
Interestingly, in the absence of SBTS, live MCF-7 cells
isolated from blood did not proliferate.
Additionally, live MCF-7 cells were further kept in
normal whole blood for 7 days at RT followed by filtra-
tion and imaging. Figure 2a shows live MCF-7 cells in
the SBTS treated blood sample with very few live MCF-
7 cells observed in whole blood in the absence of SBTS
(Fig. 2b).
We then proceeded to analyze whether the SBTS was
able to keep CTCs alive in cancer patient blood samples.
Live CTCs are fragile cells that generally need to be iso-
lated rapidly from blood samples [19–21, 26, 27]. There-
fore, extending the life of CTCs in patient blood samples
for days will increase the availability of these rare cells,
for use in real-time downstream analysis using next gen-
eration sequencing and/or proteomic analysis. Three
cancer patient blood samples (breast, prostate and lung)
were divided and incubated with or without SBTS for
6 days at RT. Blood samples were separated using ficoll,
which has been previously described in isolating viable
Fig. 1 MCF-7 cells were labeled with CellTracker™ live dye and spiked into whole blood either in the presence or absence of SBTS. After 4 days of
storage at RT, the blood sample was filtered and the filters put into tissue culture media (DMEM +10 % FBS). After 3 days in tissue culture, MCF-7
cells were dividing and forming colonies (Panel a). Insets in panel A shows higher resolutions of an MCF-7 cell stained with DAPI (left) and
CellTracker™ live dye (right) (box = 35 μm). MCF-7 cells that were incubated in whole blood for the same period did not grow (Panel b). Bar
equals 100 μm
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CTC from blood samples [41, 49–52]. The buffy coat
layer was removed and incubated with CellTracker™ Blue
CMAC cell viability stain as recommended by the
manufacturer, then cells were centrifuged to remove
free dye. Blue CMAC is a membrane permeable stain
that is well retained by live cells and is fixable by for-
maldehyde. The cells were then filtered CellSieve™
microfilters, fixed and stained with the standard CTC
marker antibodies (see Methods).
The prostate and lung cancer samples had no live
CTCs as detected by our isolation procedure, whereas
the breast cancer sample had 4 detectable live CTCs
(CMAC Blue+, CK+, EpCAM+, CD45-) after 6 days in
SBTS. The lack of CTCs isolated from the other patient
samples can be attributed to a number of factors, includ-
ing the fact that some cancer patients do not have de-
tectable CTCs in their blood samples and that the ficoll
separation step can lead to losses of CTCs [53–56].
Figure 3, panels a and b show 2 live CTCs isolated
from a breast cancer patient sample treated with SBTS
and stored for 6 days at room temperature. The cells are
alive and intact since Blue CMAC stain is retained
within the cells. Cells are also positive for cytokeratin
(green) and EpCAM (yellow), negative for CD45 and
have an intact nucleus (red).
Duplicate patient blood samples treated with buffer
and stored for 6 days at room temperature were also fil-
tered and stained. Neither live nor dead CK+, EpCAM+
cells were found on the filters of blood samples stored
without SBTS. The other 2 CTCs isolated from the
breast cancer patient sample retained the Blue CMAC
viability stain, but showed cell damage (not shown).
The data presented demonstrates that the SBTS pre-
serves cell viability, even in harsh medium such as whole
blood, which is detrimental to CTCs survival. Although
the CTCs in the breast cancer patient sample were vi-
able, we did not attempt their propagation in cell culture
because culture conditions that allows for reproducible
CTC growth without altering their phenotype has yet to
be described. However, these initial experiments which
show viability of CTCs suggest that when culture tech-
niques for CTCs are developed, the SBTS is well suited
for long term storage and transport of patient derived
blood samples.
Fig. 2 MCF-7 cells were labeled with CellTracker™ live dye and spiked into whole blood either in the presence or absence of SBTS. After 7 days of
storage at RT, the blood samples were imaged. The samples incubated with SBTS shows live MCF-7 cells (Panel a). In comparison, the absence of
SBTS, very few live MCF-7 cells were observed (Panel b). Bar equals 100 μm
A
B
Blue CMAC CK EpCAM CD45 DRAQ5 Merged
Fig. 3 Representative images of CTCs isolated from breast cancer patient whole blood. Blood sample was kept at room temperature for 6 days
and processed as described in the text. Rows a and b (from left to right) show images of captured CTCs stained for viability using Blue CMAC
(blue), cytokeratin (CK) staining (green), EpCAM staining (yellow), Alexa Fluor 594 CD45 staining (olive), DNA staining (red) and merged figures,
respectively. Bars indicate 20 μm
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Conclusions
A number of technologies have been developed to iso-
late live CTCs. However, since CTCs are rare and un-
stable in whole blood, isolation procedures must be
performed rapidly after blood collection [19–21, 26, 27].
A six day time point for blood storage SBTS was chosen
based on our results with cell culture (Table 1) and live
MCF-7 cells spiked into normal whole blood (Figs. 1
and 2). Additionally, the 6 day period was chosen to rep-
resent an extreme case for transcontinental transporta-
tion of blood samples. The benefits of having a simple,
low cost and non-toxic treatment of patient blood sam-
ples that preserves live CTC in blood samples for up to
6 days at ambient temperature will greatly enhance the
ability to analyze CTCs, because clinicians and re-
searchers will have more time to process these samples
or ship them between research facilities. M. Ignatiadis et
al. [57] succinctly wrote in their paper about this prob-
lem: “However, an important limitation of our study is
that all patients were recruited in one center and the
CTC analysis was done in one laboratory. An inter-
national, prospective, multicenter trial with different par-
ticipating laboratories in which issues of stability during
shipment of the samples, interlaboratory reproducibility
of the multimarker assay, and validation of our results in
a diverse patient population is urgently needed.”
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